{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-000164","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.351879+00:00","generated_at":"2026-06-07T01:36:37.962228+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Compass Therapeutics appoints Bisker-Leib as CEO, Schuetz to President of R&D","bullets":["Vered Bisker-Leib appointed CEO effective Jan 9, 2024; salary increased to $600k, target bonus 55%.","Thomas Schuetz transitions from CEO to President of R&D and Vice Chair of Board.","Bisker-Leib receives options for 1,753,125 shares and RSUs for 1,753,125 shares at $1.93 exercise price.","Schuetz receives options for 637,500 shares and RSUs for 637,500 shares at $1.93.","Preliminary unaudited cash, equivalents and marketable securities approx $152M as of Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-000164","json":"https://secwatch.observer/filing/0001171843-24-000164.json","markdown":"https://secwatch.observer/filing/0001171843-24-000164.md","text":"https://secwatch.observer/filing/0001171843-24-000164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/0001171843-24-000164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/f8k_010924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:36:37.962228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e1aa8fff3","claim":"Vered Bisker-Leib was appointed as Chief Executive Officer at Compass Therapeutics, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed Vered Bisker-Leib, PhD as Chief Executive Officer of the Company and a member the Board, each effective January 9, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/0001171843-24-000164-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b0b7d07e5a","claim":"Thomas Schuetz changed role as President of Research and Development at Compass Therapeutics, Inc..","evidence_excerpt":"Effective January 9, 2024, Thomas Schuetz, MD, PhD, the Company’s Scientific Founder and Chief Executive Officer and a member of the Board, will transition to President of Research and Development and be appointed Vice Chair of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/0001171843-24-000164-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"President of Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}